Intel says 14A process beats defect-reduction targets ahead of 2027 risk production

  • Intel CFO David Zinsner said 14A is exceeding its defect-reduction target curve.
  • $2.089 billion was Intel Foundry’s Q2 operating loss on $5.765 billion revenue.
  • Intel plans 14A risk production in late 2027 and high-volume manufacturing in 2028.

Intel CFO David Zinsner said the company’s upcoming 14A, a 1.4nm-class process node, is reducing defect density faster than its internal target curve. He described the improvement rate as Intel’s strongest since 22nm, while stressing that defect density does not establish final production yield. 14A is scheduled to enter risk production in the second half of 2027, followed by high-volume manufacturing in 2028. The node combines second-generation gate-all-around RibbonFET transistors, second-generation PowerDirect backside power delivery and High-NA EUV lithography. Intel is targeting 15%–20% more performance at equal power, 25%–35% lower power at equal performance and up to 30% higher density than 18A, though those remain company targets. Customer discussions have advanced from technical reviews to questions about capacity, but Intel has not announced a major binding external 14A production contract. Intel’s revenue rose 25% year over year to $16.1 billion in the second quarter, while Foundry revenue increased 31% to $5.765 billion. The division still posted a $2.089 billion operating loss, with only $293 million coming from external customers. Intel shares closed at $89.47, down 2.85%.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.